Rolle des Rezeptors für Hyaluronsäure-vermittelte Motilität (RHAMM/CD168) bei der Proliferation myeloischer Blasten

• Antragsteller: Professor Dr. Jochen Greiner
• Fachliche Zuordnung: Hämatologie, Onkologie
• Förderung: Förderung von 2005 bis 2008
• Projektkennung: Deutsche Forschungsgemeinschaft (DFG) - Projektnummer 13593725

• Erstellungsjahr: 2008

Zusammenfassung der Projektergebnisse

Keine Zusammenfassung vorhanden

Projektbezogene Publikationen (Auswahl)

• Efficient transient genetic labeling of human CD34+ progenitor cells for in vivo application. Regenerative Med 1: 223-234, 2006
  Wiehe J, Niesler C, Torzewski J, Zimmermann O, Wiesneth M, Schmitt M, Schwarz K, Donner H, Hombach V, Greiner J
  
• Expression of Tumor-Associated Antigens (TAAs) in Acute Myeloid Leukemia (AML) correlated with specific T cell responses and survival. Blood (ASH Annual Meeting Abstracts) 108:414, 2006
  Greiner J, Schmitt M, Li L, Giannopoulos K, Bösch K, Döhner K, Schmitt A, Schlenk RF, Pollack JR, Döhner H, Bullinger L
  
• Expression of tumor-associated antigens in acute myeloid leukemia: implications for specific immunotherapeutic approaches. Blood 108: 4109-17, 2006
  Greiner J, Schmitt M, Li Li, Giannopoulos K, Bösch K, Schmitt A, Döhner K, Schlenk RF, Pollack JR, Döhner H, Bullinger L
  
• Imatinib impairs the function of both CD4+ T regulatory cells and CD8+ T lymphocytes specifically directed against the leukaemia associated antigen RHAMM/CD168. Onkologie 29 (Suppl.3): P545, 2006
  Chen J, Schmitt A, Chen B, Ringhoffer M, von Harsdorf S, Greiner J, Guillaume P, Döhner H, Bunjes D, Schmitt M
  
• RHAMM/CD168 might represent potential target for immunotherapy of patients with B-cell chronic lymphocytic leukemia. CIMT, 4th Annual Meeting, 2006
  Giannopoulos K, Hus I, Li L, Bojarska-Junak A, Greiner J, Rolinski J, Dmoszynska A, Döhner H, Schmitt M
  
• RHAMM/CD168-R3 peptide vaccination of patients with hematological malignancies results in immunological and clinical responses. CIMT, 4th Annual Meeting, 2006
  Greiner J, Schmitt A, Giannopoulos K, U L, Liebisch P, Wendl C, Chen J, Ringhoffer M, Guillaume P, Ritter G, Döhner H, Schmitt M
  
• Tumor-associated antigens in acute myeloid leukemia - expression, specific T cell responses and correlation with survival. Onkologie 29 (Suppl.3): V408, 2006
  Greiner J, Schmitt M, Li L, Giannopoulos K, Bosch K, Döhner K, Chen J, Schmitt A, Schlenk R, Pollak J, Döhner H, Buliinger L
  
• Tumor-associated antigens in acute myeloid leukemia and their correlation with survival. Haematologica 91 (Suppl. 1): 0109, 2006
  Schmitt M, Greiner J, Li L, Giannopoulos K, Bosch K, Döhner K, Schlenk R, Pollak J, Döhner H, Bullinger L
  
• Highly efficient mRNA-based gene delivery into human progenitor cells. Journal of Cellular and Molecular Medicine 11:521-30,2007
  Wiehe J, Ponsaerts P, Rojewski M, Homann J, Greiner J, Kronawitter D, Schrezenmeier H, Hombach V, Wiesneth M, Zimmermann O, Torzewski J
  
• Leukaemia associated antigens and their dual role as biomarkers and therapeutical targets for acute myeloid leukaemia. Biomarkers Insights 2: 1-11, 2007
  Guinn B, Mills Kl, Czepulkowski B, Schmitt M, Greiner J
  
• Leukemia-associated antigens (LAAs) as biomarkers of survival in acute myeloid leukemia (AML). KIMT. 2007
  Greiner J, Bullinger L, Chen J, Giannopoulos K, Döhner K, Schmitt A, Schlenk RF, Pollack J, Döhner H, Schmitt M
  
• RHAMM (CD168) is overexpressed on the protein tevel and may serve as an immunogenic antigen in advanced prostate cancer disease. Proc Americ Soc Clin Oncol, 2007
  Ringhoffer M, Hofer M, Varambally S, Chinnaiyan A, Rubin M, Schmitt M, Greiner J, Kuefer R
  
• RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma elicits immunological and clinical responses. Blood, Oct 31,2007. [Epub ahead of print]
  Schmitt M, Schmitt A, Rojewski MT, Chen J, Giannopoulos K, Fei F, Yu Y, Götz M, Heyduk M, Ritter G, Speiser D, Gnjatic S, Guillaume P, Ringhoffer M, Schlenk RF, Liebisch P, Bunjes D, Shiku H, Döhner H, Greiner J
  
• RHAMM/CD168-R3 peptide vaccination of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), multiple myeloma (MM) and chronic lymphatic leukemia (CLL) elicits immunological and clinical responses. EHA 2007
  Greiner J, Schmitt A, Giannopoulos K, Chen J, Li L, Liebisch P, Ringhoffer M, Guiliaume P, Ritter G, Rojewski M, Gnjatic S, Döhner H, Schmitt M